A novel fully synthetic and self-assembled peptide solution for endoscopic submucosal dissection-induced XXXX in the stomach.

@entity1 @entity548 @entity5 @entity2318 @entity1066 @entity1003 @entity6950 @entity2275
BACKGROUND AND AIMS: Endoscopic submucosal dissection (ESD) can remove early stage @entity5 of various sizes en bloc; however, success requires reducing the relatively high postprocedure @entity548 rate. The aim of this study was to assess the safety and efficacy of a novel, fully synthetic, and self-assembled peptide solution that functions as an extracellular matrix scaffold material to facilitate reconstruction of normal tissues in ESD-induced @entity1066 . METHODS: Consecutive @entity1 who underwent gastric ESD were prospectively enrolled. Immediately after the resection, the solution was applied to the site with a catheter. @entity2275 were evaluated by endoscopy and classified as active, healing, or @entity2318 stages at weeks 1, 4, and 8 after ESD. RESULTS: Forty-seven @entity1 with 53 lesions, including 14 (29.8%) previously on antithrombotic therapy and 2 (4.3%) requiring @entity6950 bridge therapy, were analyzed; 2 @entity1 were excluded, 1 with perforations and 1 with persistent @entity1003 . The mean size of the en bloc resected specimens was 36.5    11.3  mm. The rate of post-ESD @entity548 was 2.0% (1/51; 95% CI, 0.03-10.3). Transitional rate to the healing stage of ESD-induced @entity1066 at week 1 was 96% (49/51). Subsequent endoscopies demonstrated the @entity2318 stage in 19% (9/48) and 98% (41/42) at weeks 4 and 8, respectively. No adverse effects related to this solution occurred. CONCLUSIONS: The use of this novel peptide solution may potentially aid in reducing the delayed @entity548 rate by promoting mucosal regeneration and speed of @entity1066 after large endoscopic resections in the stomach. Further studies, particularly randomized controlled studies, are needed to fully evaluate its efficacy. (Clinical trial registration number: 000011548.).
